Authors
Latest:
Dr. Spivak on Diagnosing Essential ThrombocythemiaJerry Le Pow Spivak, MD, discusses diagnosing essential thrombocythemia.
Latest:
Final Thoughts on New Developments and Emerging AgentsPanelists conclude by reviewing possible advancements on the horizon in AML such as the potential emergence of Menin inhibitors and bispecific T-cell engagers as well as improved methods for predicting response and preventing relapse.
Latest:
Dr. Kumar on Treatment Considerations with BTK Inhibitors in MCLAnita Kumar, MD, discusses considerations for the use of second-line BTK inhibitors in patients with mantle cell lymphoma who progress on BTK inhibitors.
Latest:
CLL: Final ThoughtsAn expert panel provides their final thoughts about the future of the chronic lymphocytic leukemia (CLL) treatment landscape.
Latest:
Carbone Partner Perspectives: Alcohol: The Carcinogen We’re Not Talking AboutDespite alarming figures and trends, public awareness of alcohol as a carcinogen remains low.
Latest:
Dr. Wildiers on the Final Results of the AIPAC Trial in HR+/HER2- Metastatic Breast CancerHans Wildiers, MD, medical oncologist, Department of Medical Oncology, full professor, Faculty of Medicine, member, Laboratory of Experimental Oncology, University Hospital Leuven, Leuven, Belgium, discusses the final results of the phase 2b AIPAC trial (NCT02614833) in hormone receptor (HR)–positive, HER2-negative metastatic breast cancer.
Latest:
Dr. Lee on Selecting a Treatment Approach for Neuroendocrine TumorsYoomi Lee, MD, discusses her process for selecting a treatment approach for patients with neuroendocrine tumors.
Latest:
McKesson’s Practice Insights Designated as a 2024 Qualified Clinical Data Registry by Centers for Medicare & Medicaid ServicesMcKesson has received approval from the CMS to participate in the Merit-based Incentive Payment System as a Qualified Clinical Data Registry.
Latest:
Cancer Treatment Centers of America Grows Medical Oncologist Roster Across HospitalsMedical oncologists Dr. Ajaz Khan, Dr. Ryan Engel, and Dr. Nitika Sharma are the latest board-certified, fellowship-trained physicians who have chosen to practice medicine at Cancer Treatment Centers of America®.
Latest:
Dr. Allaf on Evaluating the PROSPER-RCC Trial Results in RCCMohamad Ezzeddine Allaf, MD, discusses several key considerations when interpreting and extrapolating initial results from the phase 3 PROSPER-RCC trial in renal cell carcinoma.
Latest:
The Future of Reimbursement: How AI Can Revolutionize Oncology PracticesBy retrospectively analyzing health care financial data and using the intelligence generated to guide future claims to a more successful outcome, machine learning platforms may reduce the need for repeated insurance submissions and appeals and can improve the practice’s clean claim rate.
Latest:
Cancer Blood Tests Jumpstart Diagnoses and Targeted TherapyNew research led by a UC Davis Comprehensive Cancer Center clinical scientist shows blood tests used to hunt for cancer DNA may help detect cancers faster and guide the use of targeted therapies.
Latest:
Dr Albigès on the Efficacy of Cabozantinib in Pretreated RCCLaurence Albigès, MD, PhD, discusses on the safety and efficacy of cabozantinib in patients with unresectable, locally advanced or metastatic renal cell carcinoma with a clear cell component.
Latest:
Future Directions in the Management of Immune ThrombocytopeniaExpert panelists reflect on the advent of newer therapies in immune thrombocytopenia and look toward future evolutions in care.
Latest:
Dr Desai on the Benefits and Limitations of Bladder Preservation With Chemoradiation in MIBCNeil Desai, MD, discusses the potential benefits and limitations of utilizing chemoradiation or triple modality therapy for bladder preservation in the upfront management of patients with locally advanced, nonmetastatic muscle-invasive bladder cancer.
Latest:
Practical Advice for Management of Chronic GVHDThe panel provides advice for community providers treating patients with chronic GVHD, stressing effective communication, staying updated on evolving drugs, and collaborating with specialized multidisciplinary groups for optimal patient care.
Latest:
Long-Term Survivors of Childhood Cancer at Higher Risk of Death Following Heart Issues; Threshold for Treating Risk Factors Should Be LowerSurvivors of childhood cancer are at a significantly higher risk of death following a major cardiovascular event than the general public.
Latest:
Addition of Dalpiciclib to Fulvestrant Improves PFS in HR+ Advanced Breast CancerThe addition of dalpiciclib to fulvestrant significantly prolonged progression-free survival vs fulvestrant alone in patients with hormone receptor–positive, HER2-negative advanced breast cancer, according to data from an interim analysis of the phase 3 DAWNA-1 trial.
Latest:
Multiple Myeloma: Unmet Needs and Future Directions in CareAfter discussing earlier-line use of CAR T-cell therapy in patients with multiple myeloma, the panel considers key takeaways and future evolutions in the treatment landscape.
Latest:
Dr Hagensee on Strategies For Cervical Cancer PreventionMichael Hagensee, MD, PhD, discusses strategies for cervical cancer prevention and ongoing research investigating barriers to cervical cancer treatment.
Latest:
Dr Childs on Treatment With Olaparib Plus Abiraterone in mCRPCDan S. Childs, MD, discusses treatment with olaparib and abiraterone in metastatic castration-resistant prostate cancer.
Latest:
Dr Armaghani on the Investigation of De-Escalated Treatment Approaches in TNBCAvan Armaghani,cdiscusses the feasibility of de-escalating treatment in triple-negative breast cancer, as well as planned or ongoing research investigating this approach in the neoadjuvant and metastatic settings.
Latest:
Expanding Cancer Screening: The Future of Blood-Based TestingClosing out their panel, experts discuss the potential of blood-based tests to democratize access to cancer screening, complement existing protocols, and achieve early detection goals in the fight against cancer.
Latest:
Future Directions in Biomarker-Based OncologyExperts in oncology discuss future directions in biomarker-driven therapy.
Latest:
Patient Case 3: A 57-Year-Old Man With Cecal Colon AdenocarcinomaMichael Leung, PharmD, presents the case of a 57-year-old man with cecal colon adenocarcinoma and provides his initial thoughts, particularly on adverse event management.
Latest:
The Future of Ovarian Cancer TreatmentOncologists contemplate what ovarian cancer treatment will look like in the future and exciting clinical trials in progress.
Latest:
Dr Huddart on the FDA Approval of Erdafitinib in FGFR3+ Urothelial CancerRobert Huddart, PhD, discusses the FDA approval of erdafitinib for patients with FGFR3-altered metastatic urothelial carcinoma.
Latest:
Future of MFExperts discuss how treatments, either monotherapy or combination, may impact the treatment landscape for MF and how they might choose among the new agents.
Latest:
Key Takeaways on Evolving Bladder Cancer Treatment LandscapeThe expert panel concludes its discussion by providing key takeaways on the evolving bladder cancer treatment landscape following ESMO 2023.
